Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Gastric Cancer

Inclusion Criteria: * Age of 18years or over * Patients who had failed more than 1 cycle of standard therapy with advanced or metasatic stage and with measurable lesions * Life expectancy \>/= 5 months * Not available to any of resectable surgery or radiotherapy * Patients with adequate organ(e.g. heart, kidney, liver)and bone marrow function, as defined by 1. Absolute neutrophil count(ANC)\>/= 1.0 x 10\^9/L, Platelet count \>/= 75 x 10\^9/L 2. Total bilirubin \< 2.0mg/dL 3. Aspartate Aminotransferase(AST) and/or Alanine Aminotransferase(ALT) \< 5 x Upper Limit Normal(ULN) 4. creatinine \< 2 x ULN * ECOG status 0 to 2 * Female volunteers admitted to the study must be using a reliable means of contraception and must have a negative blood or urine pregnancy test at least 7days ago * Patients or their legal representatives who have signed the informed consent form. Exclusion Criteria: * Known brain or spinal cord metastases * Patients who have received chemotherapy within the previous 4 weeks * Patients who have received radiotherapy related tp Gastric cancer within 4weeks * Patients who have participated in other clinical study within the previous 4weeks * Pregnancy (absence to be confirmed by ß-hCG test) or lactation period * Human immunodeficiency virus(HIV) antibody (+) * Have active infection or serious concomitant systemic disorder incompatible with the study * Clinically hypertension or diabete mellitus not well controlled with medication * Clinically significant cardiac disease(e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias) or myocardial infarction * Presence or history of malignancy other than Gastirc cancer within 5years * Have severe Neurologic or psychological disorder * Patients who have history of allery with this investigational drug(SB injection) * Obvious cognitive or physical impairment that would prevent participation